NBSEinactive
NeuBase Therapeutics, Inc.
Biopharma developer (SEC filing verified)·Pre-clinical·CEO: Todd Branning
Todd
OncologyRare Disease
Run NeuBase Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NeuBase Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Frequently asked questions
Who is the CEO of NeuBase Therapeutics, Inc.?
Todd Branning Todd is the chief executive officer of NeuBase Therapeutics, Inc. (NBSE).
What therapeutic areas does NeuBase Therapeutics, Inc. focus on?
NeuBase Therapeutics, Inc. develops therapies across Oncology, Rare Disease.
923 companies304,844 SEC filings22,644 clinical trials100% citation-verification pass rate (7d)How we verify →
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.